,2 Presently, cerebrospinal fluid (CSF) measures of Aβ and tau levels, along with positron emission tomography (PET) imaging with Aβ and tau ligands, and MRI assessment of brain atrophy, are the established tools to support in vivo diagnosis of AD.3 This evidence concerns the gene MAPT and Alzheimer disease.